Dr Alva is a board-certified psychiatrist, a paid consultant of Otsuka America Pharmaceutical, Inc, and Lundbeck, and Mood Disorders Section Editor for Psychiatric Times.
The Role of Prescription Digital Therapeutics in the Schizophrenia Treatment Landscape
April 22nd 2025Gus Alva, MD, discusses how he will be examining notable challenges in schizophrenia care, including access issues, and exploring the potential role of prescription digital therapeutics in addressing these gaps.
Final Pearls: Changing Possibilities in MDD Management
Clinicians wrap up their discussion on novel, rapid-acting agents for major depressive disorder (MDD) with key insights and takeaways for providers.
Clinical Insights: Second Case Analysis of MDD
Clinicians expand their discussion with a second patient case, highlighting similarities and differences between cases, and particular treatment algorithms that may be helpful.
Responding With Treatment: Clinical Perspectives on First MDD Case
Experts continue their discussion of the first patient case, explaining how glutamate-modulating therapies could help improve his symptoms and outcomes.
Clinical Insights: First Case Analysis of MDD
Experts use a major depressive disorder (MDD) patient case to provide clinical insights on managing MDD, and how they would educate patients about their condition.
Current Landscape of Rapid-Acting Therapies for MDD
Experts highlight the current and prospective therapies for patients with MDD, highlighting key similarities and differences in patient pathophysiology, drug onset of action, and overall therapeutic limitations.
Anhedonia and Cognitive Dysfunction: Glutamate Modulation's Impact
Experts discuss the impact of targeting glutamate receptors, highlighting its positive effects for patients with anhedonia.
Shifting Paradigms: The Future Role of Rapid Acting Antidepressants
Experts discuss the need to review current clinical guidelines in light of the need for rapid-acting treatment, especially as first-line treatments for some patients.
Hopeful Horizons: The Potential of Rapid Acting Therapies in MDD
Clinicians discuss the particular benefits of rapid-acting agents for major depressive disorder (MDD), highlighting the gap glutamate-modulating agents fill in targeted therapies.